Predictors of non-adherence to pharmacotherapy in patients with type 2 diabetes

International Journal of Clinical Pharmacy

Volumn 36, Issue 4, 2014, Pages 725-733

  Jarab, Anan S ^a   Almrayat, Reham ^b   Alqudah, Salam ^b   Thehairat, Ekbal ^b   Mukattash, Tareq L ^c   Khdour, Maher ^d   Pinto, Sharrel ^e  

^a AL ZAYTOONAH UNIVERSITY OF JORDAN   (Jordan)

^b Department of Pharmacy Royal Medical Services Hospital ^*  (Jordan)

^c JORDAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Jordan)

^d AL QUDS UNIVERSITY   (Palestine)

^e UNIVERSITY OF TOLEDO   (United States)

Author keywords

Adherence; Glycemic control; Jordan; Type 2 diabetes

Indexed keywords

ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; GLUCOSE; INSULIN; METFORMIN; SULFONYLUREA; ANTIDIABETIC AGENT;

ADULT; AGE; ARTICLE; ATTITUDE TO HEALTH; DIABETIC PATIENT; EDUCATION; FEMALE; GENDER; GLUCOSE BLOOD LEVEL; HUMAN; INSULIN TREATMENT; JORDAN; MAJOR CLINICAL STUDY; MALE; MARRIAGE; NON INSULIN DEPENDENT DIABETES MELLITUS; OCCUPATION; PATIENT COMPLIANCE; PHARMACEUTICAL CARE; PREDICTION; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; SELF MONITORING; SMOKING; VISUAL ANALOG SCALE; ADVERSE EFFECTS; AGED; BIOLOGICAL MODEL; COMPLICATION; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; DRUG ADMINISTRATION; DRUG COMBINATION; FOLLOW UP; HOSPITAL; MEDICATION COMPLIANCE; MIDDLE AGED; OUTPATIENT DEPARTMENT; PERIPHERAL VASCULAR DISEASES; PERSONALIZED MEDICINE; STATISTICAL MODEL;

AGED; DIABETES MELLITUS, TYPE 2; DIABETIC ANGIOPATHIES; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; FOLLOW-UP STUDIES; HEALTH KNOWLEDGE, ATTITUDES, PRACTICE; HOSPITALS, URBAN; HUMANS; HYPOGLYCEMIC AGENTS; INDIVIDUALIZED MEDICINE; JORDAN; LOGISTIC MODELS; MALE; MEDICATION ADHERENCE; METFORMIN; MIDDLE AGED; MODELS, BIOLOGICAL; OUTPATIENT CLINICS, HOSPITAL; PERIPHERAL VASCULAR DISEASES; QUALITY OF LIFE;

EID: 84905987883     PISSN: 22107703     EISSN: 22107711     Source Type: Journal    
DOI: 10.1007/s11096-014-9938-5     Document Type: Article

References (44)

1. Ajlouni K, Khader YS, Batieha A, Ajlouni H, El-Khateeb M. An increase in prevalence of diabetes mellitus in Jordan over 10 years. J Diabetes Complications. 2008;22(5):317-24.
2. Waly MI, Essa MM, Ali A, Al-Shuaibi YM, Al-Farsi YM. The global burden of type 2 diabetes: a review. Int J Biol Med Res. 2010;1(4):326-9.
3. Ajlouni K, Jaddou H, Batieha A. Diabetes and impaired glucose tolerance in Jordan: prevalence and associated risk factors. J Intern Med. 1998;244(4):317-23. (Pubitemid 28473995)
4. World Health Organization. Noncommunicable diseases: country profiles. 2011. ISBN:9789241502283.
5. American Diabetes Association. Implications of the United Kingdom prospective diabetes study. Diabetes Care. 2003;26(Suppl 1):S28-32.
6. Khattab M, Khader YS, Al-Khawaldeh A, Ajlouni K. Factors associated with poor glycemic control among patients with type 2 diabetes. J Diabetes Complic. 2010;24:84-9.
7. Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000;321(7258):405-12. (Pubitemid 30609442)
8. Karter AJ, Moffet HH, Liu J, Parker MM, Ahmed AT, Ferrara A, et al. Achieving good glycemic control: initiation of new anti hyperglycemic therapies in patient with type 2 diabetes from the Kaiser Permanente Northern California diabetes registry. Am J Manag Care. 2005;11(4):262-70. (Pubitemid 40569749)
9. World Health Organization. Adherence to long-term therapies: evidence for action. Geneva; 2003. ISBN: 92 4 154599 2. http:// whqlibdoc.who.int/ publications/2003/9241545992.pdf.
10. Armour CL, Taylor SJ, Hourihan F. Implementing and evaluation of Australian pharmacists' diabetes care services. J Am Pharm Assoc. 2004;44(4):455-66.
11. Cramer J. A systemic review of adherence with medications for diabetes. Diabetes Care. 2004;27:1218-24. (Pubitemid 38579798)
12. Bezie Y, Molina M, Hernandez N, Batista R, Niang S, Huet D. Therapeutic compliance: a prospective analysis of various factors involved in the adherence rate in type 2 diabetes. Diabetes Metab. 2006;32(6):611-6. (Pubitemid 46145374)
13. McDonald HP, Garg AX, Haynes RB. Interventions to enhance patient adherence to medication prescriptions: scientific review. JAMA. 2002;288(22):2868-79. (Pubitemid 35425073)
14. Irons BK, Lenz RJ, Anderson SL, Wharton BL, Habeger B, Anderson HG. A retrospective cohort analysis of the clinical effectiveness of a physician-pharmacist collaborative drug therapy management diabetes clinic. Pharmacotherapy. 2002;22(10):1294-300. (Pubitemid 35155082)
15. Armitage CJ, Conner M. Social cognition models and health behaviour: a structured review. Psychol Health. 2000;15(2):173-89.
16. Jarab AS, Alqudah SG, Mukattash TL, Shattat G, Al-Qirim T. Randomized controlled trial of clinical pharmacy management of patients with type 2 diabetes in an outpatient diabetes clinic in Jordan. JMCP. 2012;18(7):516-26.
17. Morisky DE, Green LW, Levine DM. Concurrent and predictive validity of a self-reported measure of medication adherence. MedCare. 1986;24(1):67-74. (Pubitemid 16125389)
18. Speight J, Bradley C. The ADKnowl: identifying knowledge deficits in diabetes care. Diabet Med. 2001;18(8):626-33. (Pubitemid 32823059)
19. EuroQol-a new facility for the measurement of health-related quality of life. The EuroQol Group. Health Policy. 1990;16(3):199-208.
20. Krabbe P, Weijnen T. Guidelines for analysing and reporting EQ-5D outcomes. The measurement and valuation of health status using EQ-5D: A European Perspective. Edited by Brooks R, Rabin R, De Charro F. Dordrecht: Kluwer Academic Publishers. 2003;7-19. ISBN: 978-94-017-0233-1.
21. Sakamaki H, Ikeda S, Ikegami N, Uchigata Y, Iwamoto Y, Origasa H, et al. Measurement of HRQL using EQ-5D in patients with type 2 diabetes mellitus in Japan. Value Health. 2006;9(1):47-53.
22. Field A. Discovering statistics using SPSS. (3rd edition). 2009; London: Sage. ISBN: 978-1-84787907-3.
23. Hosmer DW, Lemeshow S. Applied logistic regression. 2nd ed. New York; 2000. ISBN: 0-471-35632-8.
24. Nichols-English G, Poirier S. Optimizing adherence to pharmaceutical care plans. J Am Pharm Assoc. 2000;40(4):475-85.
25. Krapek K, King K, Warren S, George K, Caputo D, Mihelich K, et al. Medication adherence and associated hemoglobin A1c in type 2 diabetes. Ann Pharmacother. 2004;38(9):1357-62. (Pubitemid 39100184)
26. Venturini F, Nichol MB, Sung JC, Bailey KL, Cody M, McCombs JS. Compliance with sulfonylureas in a health maintenance organization: a pharmacy record-based study. Ann Pharmacother. 1999;33(3):281-8. (Pubitemid 29157736)
27. George CF, Peveler RC, Heiliger S, Thompson C. Compliance with tricyclic antidepressants: the value of four different methods of assessment. Br J Clin Pharmacol. 2000;50(2):166-71. (Pubitemid 30612035)
28. Patel RP, Taylor SD. Factors affecting medication adherence in hypertensive patients. Ann Pharmacother. 2002;36(1):40-5. (Pubitemid 34052941)
29. Horne R, Weinman J. Patients' beliefs about prescribed medicines and their role in adherence to treatment in chronic physical illness. J Psychosom Res. 1999;47(6):555-67. (Pubitemid 30029305)
30. Kripalani S, Risser J, Gatti ME, Jacobson TA. Development and evaluation of the adherence to refills and medications scale (ARMS) among low literacy patients with chronic disease. Value Health. 2009;12(1):118-23.
31. Guillausseau PJ. Influence of oral antidiabetic drugs compliance on metabolic control in type 2 diabetes. Diabetes Metab. 2003;29(1):79-81. (Pubitemid 36362620)
32. Shaw KM. Overcoming the hurdles to achieving glycemic control. Metabolism. 2006;55(5 Suppl 1):S6-9. (Pubitemid 44316687)
33. McNabb WL. Adherence in diabetes: can we define it and can we measure it? Diabetes Care. 1997;20(2):215-8. (Pubitemid 27051566)
34. Lee VW, Leung PY. Glycemic control and medication compliance in diabetic patients in a pharmacist-managed clinic in Hong Kong. Am J Health Syst Pharm. 2003;60(24):2593-6. (Pubitemid 44712862)
35. Lerman I, Lozano L, Villa AR, Hernández-Jiménez S, Weinger K, Caballero AE, et al. Psychosocial factors associated with poor diabetes self-care management in a specialized Center in Mexico City. Biomed Pharmacother. 2004;58(10):566-70. (Pubitemid 40260378)
36. Dailey G, Kim MS, Lian JF. Patient compliance and persistence with antihyperglycemic drug regimens: evaluation of a Medicaid population with type 2 diabetes mellitus. Clin Ther. 2001;23(8):1311-20. (Pubitemid 32804123)
37. Donnan PT, MacDonald TM, Morris AD. Adherence to prescribed oral hypoglycaemic medication in a population of patients with type 2 diabetes: a retrospective cohort study. Diabet Med. 2002;19(4):279-84. (Pubitemid 34592152)
38. Melikian C, White TJ, Vanderplas A, Dezii CM, Chang E. Adherence to oral antidiabetic therapy in a managed care organization a comparison of monotherapy, combination therapy, and fixed-dose combination therapy. Clin Ther. 2002;24(3):460-7. (Pubitemid 34275867)
39. Lerman I. Adherence to treatment: the key for avoiding long-term complications of diabetes. Arch Med Res. 2005;36(3):300-6. (Pubitemid 40762580)
40. Rubin RR. Adherence to pharmacologic therapy in patients with type 2 diabetes mellitus. Am J Med. 2005;118(Suppl 5A):S27-34.
41. Paes AH, Bakker A, Soe-Agnie CJ. Impact of dosage frequency on patient compliance. Diabetes Care. 1997;20(10):1512-7. (Pubitemid 27415025)
42. George J, Kong DC, Thoman R, Stewart K. Factors associated with medication non adherence in patients with COPD. Chest. 2005;128(5):3198-204. (Pubitemid 41698641)
43. Morningstar BA, Sketris IS, Kephart GC, Sclar DA. Variation in pharmacy prescription refill adherence measures by type of oral anti hyperglycaemic drug therapy in seniors in Nova Scotia, Canada. J Clin Pharm Ther. 2002;27(3):213-20. (Pubitemid 34748147)
44. Glasgow RE, Toobert DJ, Gillette CD. Psychological barriers to diabetes self management and quality of life. Diabetes Spectr. 2001;14(1):33-41.